Pressure BioSciences, Inc. (PBIO-OTC), a company that develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market, will hold a conference call to update investors on its business and financial results on Thursday, August 14, 2014. The call will cover the company's financial results for the second quarter 2014.
To attend this investor update tomorrow, use the following dial-in information:
For a replay of the call, use the following dial-in information (replay only available for 90 days).
A replay will also be made available on Pressure BioSciences' corporate website.
Pressure BioSciences, Inc. develops and commercializes proprietary laboratory instruments and consumable products. Its product portfolio is based on its patented pressure cycling technology (PCT) platform, which is able to apply and release high levels of hydrostatic pressure in a safe and controlled manner. While this technology has applications across many industries, Pressure BioSciences is initially using PCT to develop products that improve sample preparation—the process of preparing a sample for analysis. In life science research, sample preparation is integral to tens of thousands of laboratories worldwide.
Pressure BioSciences’ line of Barocycler® products enables scientists to harness the power of PCT in the lab. Biological samples (e.g., cells and tissues from humans, animals, plants) placed in a Barocycler are exposed to programmable cycles of low-to-intense pressure—up to 100,000 pounds per square inch (psi). This act of “cycling” pressure can accelerate and control physical and chemical processes, including the breakup of cellular structures and release of biomarkers from a sample for testing and analysis. Pressure BioSciences’ portfolio also includes Shredder instruments (for rapidly shredding or grinding samples), sample preparation kits and reagents, and related consumable products (e.g., tubes to hold the samples during the PCT process).
To date, the company has installed over 250 of its PCT systems in approximately 160 sites worldwide. The technology has been the subject of over 100 publications globally, which have supported Pressure BioSciences' development and sales efforts in the biomarker discovery, drug discovery and design, and forensics sectors primarily as well as in bio-therapeutics characterization, soil and plant biology, vaccine development, and counter-bioterror applications.
* * * * * * * * * * *
* * * * * * * * * * *